The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.

Ann Clin Transl Neurol · 2018 · PMC5989782 · PMID 29928654

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

showed a trendP = 0.059so close (0.05 < p ≤ 0.1)

Patients treated with protocol 4 showed a trend to a higher risk of relapse than those treated with protocol 4 + 2 ( HR 9.2, 95% CI 0.9–91.8, P = 0.059).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.